Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Obesity Surgery
Published in: Obesity Surgery 11/2008

01-11-2008 | Research Article

Different Effect of Laparoscopic Roux-en-Y Gastric Bypass and Open Biliopancreatic Diversion of Scopinaro on Serum PYY and Ghrelin Levels

Authors: E. Garcia-Fuentes, L. Garrido-Sanchez, J. M. Garcia-Almeida, J. Garcia-Arnes, J. L. Gallego-Perales, J. Rivas-Marin, S. Morcillo, I. Cardona, F. Soriguer

Published in: Obesity Surgery | Issue 11/2008

Login to get access

Abstract

Background

The impact of bariatric surgery on levels of peptide YY (PYY) and ghrelin is still under discussion. We undertook a simultaneous evaluation of the serum changes in PYY and ghrelin depending on the specific type of bariatric surgery.

Methods

Total PYY and ghrelin were analyzed in 29 healthy persons and in morbidly obese persons undergoing open biliopancreatic diversion (BPD) of Scopinaro (n = 38) or laparoscopic Roux-en-Y gastric bypass (RYGB; n = 13).

Results

RYGB resulted in a significantly greater loss of weight and body mass index than BPD. Both RYGB and BPD were associated with a significant increase in PYY, significantly greater for BDP (p = 0.001). Ghrelin rose significantly after RYGB (p = 0.022) but not after BPD. After surgery, PYY correlated positively with weight (r = 0.416, p = 0.009). Ghrelin did not correlate significantly with any of the variables studied. Analysis of variance showed that only the type of surgery contributed significantly to explain the variances in the PYY (p = 0.002) and ghrelin (p = 0.018).

Conclusions

BPD results in a greater increase in PYY and a lower weight loss than RYGB. However, only RYGB was associated with a significant increase in ghrelin. The differing weight loss according to the type of bariatric surgery does not seem to be explained by changes arising in PYY and ghrelin.
Literature
1.
Batterham RL, Cowley MA, Small CJ, et al. Gut hormone PYY (3–36) physiologically inhibits food intake. Nature. 2002;418:650–4.PubMedCrossRef
2.
Ballantyne GH. Peptide YY(1–36) and peptide YY(3–36): part I. Distribution, release and actions. Obes Surg. 2006;16:651–8.PubMedCrossRef
3.
Ballantyne GH. Peptide YY(1–36) and peptide YY(3–36): part II. Changes after gastrointestinal surgery and bariatric surgery. Obes Surg. 2006;16:795–803.PubMedCrossRef
4.
5.
Ueno H, Yamaguchi H, Kangawa K, et al. Ghrelin: a gastric peptide that regulates food intake and energy homeostasis. Regul Pept. 2005;15(126):11–9.CrossRef
6.
Stratis C, Alexandrides T, Vagenas K, et al. Ghrelin and peptide YY levels after a variant of biliopancreatic diversion with Roux-en-Y gastric bypass versus after colectomy: a prospective comparative study. Obes Surg. 2006;16:752–8.PubMedCrossRef
7.
Korner J, Bessler M, Cirilo LJ, et al. Effects of Roux-en-Y gastric bypass surgery on fasting and postprandial concentrations of plasma ghrelin, peptide YY, and insulin. J Clin Endocrinol Metab. 2005;90:359–65.PubMedCrossRef
8.
Tschop M, Weyer C, Tataranni PA, et al. Circulating ghrelin levels are decreased in human obesity. Diabetes. 2001;50:707–9.PubMedCrossRef
9.
Shiiya T, Nakazato M, Mizuta M, et al. Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. J Clin Endocrinol Metab. 2002;87:240–4.PubMedCrossRef
10.
Roth CL, Enriori PJ, Harz K, et al. Peptide YY is a regulator of energy homeostasis in obese children before and after weight loss. J Clin Endocrinol Metab. 2005;90:6386–91.PubMedCrossRef
11.
Stock S, Leichner P, Wong AC, et al. Ghrelin, peptide YY, glucose-dependent insulinotropic polypeptide, and hunger responses to a mixed meal in anorexic, obese, and control female adolescents. J Clin Endocrinol Metab. 2005;90:2161–8.PubMedCrossRef
12.
Alvarez-Bartolome M, Borque M, Martinez-Sarmiento J, et al. Peptide YY secretion in morbidly obese patients before and after vertical banded gastroplasty. Obes Surg. 2002;12:324–7.PubMedCrossRef
13.
Naslund E, Gryback P, Hellstrom PM, et al. Gastrointestinal hormones and gastric emptying 20 years after jejunoileal bypass for massive obesity. Int J Obes. 1997;21:387–92.CrossRef
14.
MacLean LD, Rhode BM, Nohr CW. Long- or short-limb gastric bypass? J Gastrointest Surg. 2001;5:525–30.PubMedCrossRef
15.
Adrian TE, Ferri GL, Bacarese-Hamilton AJ, et al. Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology. 1985;89:1070–7.PubMed
16.
Lin HC, Taylor IL. Release of peptide YY by fat in the proximal but not distal gut depends on an atropine-sensitive cholinergic pathway. Regul Pept. 2004;117:73–6.PubMedCrossRef
17.
Lee H, Te C, Koshy S, et al. Does ghrelin really matter after bariatric surgery? Surg Obes Relat Dis. 2006;2:538–48.PubMedCrossRef
18.
Kotidis EV, Koliakos GG, Baltzopoulos VG, et al. Serum ghrelin, leptin and adiponectin levels before and after weight loss: comparison of three methods of treatment—a prospective study. Obes Surg. 2006;16:1425–32.PubMedCrossRef
19.
Cummings DE, Weigle DS, Frayo RS, et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med. 2002;346:1623–30.PubMedCrossRef
20.
Frühbeck G, Rotellar F, Hernández-Lizoain JL, et al. Fasting plasma ghrelin concentrations 6 months after gastric bypass are not determined by weight loss or changes in insulinemia. Obes Surg. 2004;14:1208–15.PubMedCrossRef
21.
Faraj M, Havel PJ, Phelis S, et al. Plasma acylation-stimulating protein, adiponectin, leptin, and ghrelin before and after weight loss induced by gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab. 2003;88:1594–602.PubMedCrossRef
22.
García-Unzueta MT, Fernández-Santiago R, Domínguez-Díez A, et al. Fasting plasma ghrelin levels increase progressively after biliopancreatic diversion: one-year follow-up. Obes Surg. 2005;15:187–90.PubMedCrossRef
23.
Adami GF, Cordera R, Andraghetti G, et al. Changes in serum ghrelin concentration following biliopancreatic diversion for obesity. Obes Res. 2004;12:684–7.PubMedCrossRef
24.
Frühbeck G, Diez-Caballero A, Gil MJ, et al. The decrease in plasma ghrelin concentrations following bariatric surgery depends on the functional integrity of the fundus. Obes Surg. 2004;14:606–12.PubMedCrossRef
25.
Fetner R, McGinty J, Russell C, et al. Incretins, diabetes, and bariatric surgery: a review. Surg Obes Relat Dis. 2005;1:589–97.PubMedCrossRef
26.
Konturek SJ, Konturek JW, Pawlik T, et al. Brain–gut axis and its role in the control of food intake. J Physiol Pharmacol. 2004;55(1 Part 2):137–54.PubMed
27.
Higgins SC, Gueorguiev M, Korbonits M. Ghrelin, the peripheral hunger hormone. Ann Med. 2007;39:116–36.PubMedCrossRef
28.
Boggiano MM, Chandler PC, Oswald KD, et al. PYY3-36 as an anti-obesity drug target. Obes Rev. 2005;6:307–22.PubMedCrossRef
29.
Tschop M, Castaneda TR, Joost HG, et al. Physiology: does gut hormone PYY3–36 decrease food intake in rodents? Nature. 2004;430:162–5.CrossRef
30.
Holdstock C, Engstrom BE, Ohrvall M, et al. Ghrelin and adipose tissue regulatory peptides: effect of gastric bypass surgery in obese humans. J Clin Endocrinol Metab. 2003;88:3177–83.PubMedCrossRef
31.
Gualillo O, Lago F, Gomez-Reino J, et al. Ghrelin, a widespread hormone: insights into molecular and cellular regulation of its expression and metabolism of action. FEBS Lett. 2003;552:105–9.PubMedCrossRef
32.
Leidy HJ, Gardner JK, Frye BR, et al. Circulating ghrelin is sensitive to changes in body weight during a diet and exercise program in normal-weight young women. J Clin Endocrinol Metab. 2004;89:2659–64.PubMedCrossRef
33.
Pfluger PT, Kampe J, Castaneda TR, et al. Effect of human body weight changes on circulating levels of peptide YY and peptide YY3-36. J Clin Endocrinol Metab. 2007;92:583–8.PubMedCrossRef
Metadata
Title
Different Effect of Laparoscopic Roux-en-Y Gastric Bypass and Open Biliopancreatic Diversion of Scopinaro on Serum PYY and Ghrelin Levels
Authors
E. Garcia-Fuentes
L. Garrido-Sanchez
J. M. Garcia-Almeida
J. Garcia-Arnes
J. L. Gallego-Perales
J. Rivas-Marin
S. Morcillo
I. Cardona
F. Soriguer
Publication date
01-11-2008
Publisher
Springer-Verlag
Published in
Obesity Surgery / Issue 11/2008
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-008-9560-5

Other articles of this Issue 11/2008

Obesity Surgery 11/2008 Go to the issue

Research Article

Circumferential Abdominoplasty

Review

Prevention of Vitamin and Mineral Deficiencies After Bariatric Surgery: Evidence and Algorithms

Research Article

Laparoscopic vs Open Gastric Bypass in the Management of Morbid Obesity: A 7-year Retrospective Study of 1,364 Patients from a Single Center

Research Article

BioEnterics Intragastric Balloon for Treatment of Morbid Obesity in Prader–Willi Syndrome: Specific Risks and Benefits

Case Report

Late Presentation of a Diaphragmatic Hernia Following Laparoscopic Gastric Banding

Case Report

Fatal Fulminant Pancreatitis After Laparoscopic Gastric Bypass Surgery